Farther Finance Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Farther Finance Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$449	Sell	39 -387	-91%	-$5.39K	﹤0.01%	5772
2026 Q2	$6.36K	Buy	426 +387	+992%	+$5.37K	﹤0.01%	4661
2026 Q1	$563	Sell	39 -284	-88%	-$4.53K	﹤0.01%	5241
2025 Q4	$2.49K	Buy	+323	New	+$2.55K	﹤0.01%	4603

Other funds holding CRVS

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

AIM

Avity Investment Management Greenwich, Connecticut $1.6B AUM 32.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors's CRVS Position: Q3 2026 in Review

Farther Finance Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 91% in Q3 2026, selling an estimated $5.39K and leaving 39 shares worth $449. The position accounts for ﹤0.01% of the portfolio, ranked #5772.

Farther Finance Advisors first reported a position in CRVS in Q4 2025 and has held it in 4 quarters since. The position peaked at $6.36K in Q2 2026. 6 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

Farther Finance Advisors held 39 shares of Corvus Pharmaceuticals worth $449 as of Q3 2026.
Farther Finance Advisors sold 387 Corvus Pharmaceuticals shares in Q3 2026, an estimated $5.39K.
Corvus Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5772 holding.
Farther Finance Advisors first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
Farther Finance Advisors's Corvus Pharmaceuticals position peaked at $6.36K in Q2 2026.
6 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.